Dolutegravir/lamivudine (Dovato®) recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus type 1 (HIV-1)

It is recommended for use in adults and adolescents aged >12 years, weighing ≥40 kg, with no known/suspected resistance to integrase inhibitor class, or lamivudine, contingent on approved Wales Patient Access Scheme (WPAS) or where list/contract price is equivalent or <WPAS price

All Wales Medicines Strategy Group